| Literature DB >> 22200164 |
Neng-Chyan Huang1, Shue-Ren Wann, Hong-Tai Chang, Shoa-Lin Lin, Jyh-Seng Wang, How-Ran Guo.
Abstract
BACKGROUND: Hepatic angiosarcoma (HAS) is a rare type of liver cancer that is often fatal, and arsenic and vinyl chloride monomer (VCM) are two major causal agents. Whereas Taiwan is an endemic area of liver cancer, epidemiologic data on HAS are limited. We reviewed the cases observed at a teaching hospital to evaluate the roles of VCM, arsenic, and viral hepatitis in the occurrence of HAS.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22200164 PMCID: PMC3280174 DOI: 10.1186/1471-230X-11-142
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Clinical features of patients of hepatic angiomyosarcoma
| Case | Sex | Age (year) | Chief Complaint | Comobidity | Alcohol Drinking | Hepatitis | Treatment | Metastasis | Follow-up | Immunostaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 65 | liver tumor | DM | yes | none | C | none | 3 M | CD31, Factor VIII |
| 2 | M | 62 | abdominal pain | HTN, gout | No | none | C | none | 1 W | CD31, vimentin |
| 3 | M | 67 | right subcostal pain | DM, HTN | No | none | OP+C/T | lung, subphrenic, peritoneum | 44 M | CD31, CD34, Factor VIII, FLI-1, vimentin, |
| 4 | F | 69 | general weakness | DM, HTN, gastric GIST | No | none | OP+C/T+R/T | brain, spine | 37 M | CD31 |
| 5 | M | 83 | general edema | HTN, CAD, COPD | No | none | C | none | 8 M | CD31 |
| 6 | M | 56 | epigastric mass | DM, HTN, liver rupture | No | none | TAE+OP | none | 4 M | CD31 |
| 7 | F | 60 | liver tumor | hypothyroidism, uremia | No | HCV | C | none | 2 M | CD34 |
| 8 | F | 63 | right abdominal pain | liver rupture | No | none | OP+C/T | peritoneum, duodeum, colon | 3 M | CD31 |
| 9 | M | 56 | liver tumor | L/C, EV, left hip AVN | yes | HCV | TAE+HAIC | none | 24 M | CD31, CD34, D2-40, c-kit, Factor VIII |
DM = diabetes mellitus; HTN = hypertension; GIST = gastrointestinal stromal tumor; CAD = coronary arterial disease; COPD = chronic obstructive pulmonary disease; L/C = liver cirrhosis; EV = esophageal varies; AVN = avscular necrosis; OP = operation; TAE = transarterial embolization; C/T = chemotherapy; C = conservative treatment; HAIC = hepatic arterial infusion chemotherapy; M = month; W = week.
Figure 1The abdominal computed tomograph in a patient of hepatic angiosarcoma (Case 9). A low-density mass (3.5 cm) with persistent contrast enhancement (29/54/68 hu) in left hepatic lobe is noted (arrowhead) (left: non-contrast phase, right: venous phase). Several enhancing lesions (1-3 cm) in right lobe of liver S5 are not well demonstrated in the venous phase (not shown in figure). Irregular liver surface, splenomegaly, and collateral circulation are noted, indicating cirrhosis.
Demographic data on patients of hepatic angiomyosarcoma
| Men | Women | ||
|---|---|---|---|
| Number of patients | 6 (66.7%)a | 3 (33.3%)a | |
| Max. tumor size (cm) | 8.9 ± 3.4 (3.9-13.5) | 13.5 ± 7.1 (8.4-18.5) | 0.51 |
| Age (year) | 64.8 ± 10.0 (56-83) | 64.0 ± 4.6 (60-69) | 0.80 |
| Pathology | 0.52 | ||
| FNA | 4 | 1 | |
| Surgery | 2 | 2 | |
| Treatment | 0.45 | ||
| Operation | 1 | 0 | |
| OP+C/T | 1 | 1 | |
| OP+C/T+R/T | 0 | 1 | |
| TAE+HAIC | 1 | 0 | |
| TAE+OP | 1 | 0 | |
| Conservative | 3 | 1 | |
| Metastasis | 1 | 2 | 0.23 |
| Liver rupture | 1 | 1 | > 0.95 |
| Hepatitis | > 0.95 | ||
| HCV | 1 | 1 | |
| Alcohol drinking | 2 | 0 | 0.50 |
| Uremia in HD | 0 | 1 | 0.33 |
All data of tumor size and age expressed as mean ± standard deviation; FNA = fine needle aspiration; OP = operation; C/T = chemotherapy; R/T = radiotherapy; HAIC = hepatic arterial infusion chemotherapy; TAE = transarterial embolization; HCV = hepatitis C virus; HD = hemodialysis.
aData express as percentage (%) of all patients.
Figure 2The pathological features of hepatic angiosarcoma (Case 9). The sections of the specimen show a picture of liver tissue with sheets of spindle tumor cells with focal necrosis (Left, H&E stain, x200). Focal vascular channels are also lined by atypical cells. The tumor cells show positive staining in the CD31 (Right, x200), CD34, factor VIII, D2-40 and c-kit stains, and negative for AE1/AE3, hepatocyte, S100, and HHF-35 stains.
Laboratory data of patients of hepatic angiosarcoma
| Variable | All (n = 9) | Men (n = 6) | Women (n = 3) | |
|---|---|---|---|---|
| WBC (/Cumm) | 7461 ± 2785 | 5806 ± 1471 | 10770 ± 995 | 0.02 |
| Hgb (g%) | 12.1 ± 1.8 | 12.7 ± 2.0 | 10.8 ± 0.6 | 0.24 |
| Platelet (k/Cumm) | 176.2 ± 104.6 | 182.2 ± 73.2 | 164.3 ± 173.3 | 0.61 |
| Blood Sugar (mg/dL) | 147.3 ± 53.5 | 158.2 ± 63.9 | 125.7 ± 13.7 | > 0.95 |
| BUN (mg/dL) | 14.0 ± 4.9 | 15.3 ± 5.3 | 14.4 ± 8.0 | 0.50 |
| Creatinine (mg/dL) | 1.7 ± 2.1 | 1.1 ± 0.2 | 3.0 ± 3.7 | 0.90 |
| Sodium (mmol/L) | 137.1 ± 2.5 | 138.0 ± 1.7 | 135.3 ± 3.2 | 0.24 |
| Potasium (mmol/L) | 3.9 ± 0.6 | 4.0 ± 0.4 | 3.8 ± 1.1 | 0.80 |
| Calcium (mg/dL) | 9.2 ± 0.7 | 9.0 ± 0.2 | 9.4 ± 1.4 | > 0.95 |
| T-Bilirubin (U/L) | 3.4 ± 7.1 | 1.0 ± 0.6 | 10.8 ± 14.3 | 0.50 |
| AST (U/L) | 39.1 ± 17.9 | 42.3 ± 19.1 | 29.5 ± 13.4 | 0.40 |
| ALT (U/L) | 28.9 ± 17.5 | 32.5 ± 18.0 | 21.7 ± 17.4 | 0.44 |
| ALP (U/L) | 171.4 ± 77.4 | 164.0 ± 68.6 | 193.5 ± 130.8 | 0.74 |
| rGT (U/L) | 131.3 ± 23.2 | 120.0 ± 0.0 | 137.0 ± 29.7 | > 0.95 |
| CK (U/L) | 47.0 ± 20.8 | 46.5 ± 14.8 | 47.3 ± 27.5 | > 0.95 |
| Amylase (U/L) | 36.3 ± 8.5 | 38.0 ± 11.3 | 33.0 ± 0.0 | > 0.95 |
| Albumin (g/L) | 3.5 ± 0.3 | 3.6 ± 0.3 | 3.5 ± 0.0 | 0.76 |
WBC = white cell count; Hgb = hemoglobulin; BUN = blood urea nitrogen; AST = aspartate aminotransferase; ALT = alanine aminotransferase; rGT = r-Glutamyl Transpeptidase; CK = creatine kinase.
Previously reported cases of hepatic angiomyosarcoma in Taiwan
| Reference | Sex | Age | Chief Complaint | Comobidity | Alcohol Drinking | Hepatitis | Treatment | Metastasis | Follow-up | Immunostaining |
|---|---|---|---|---|---|---|---|---|---|---|
| Weng et al. [ | M | 42 | fever | none | no | none | TAE+OP | none | 7 M | Factor VIII, UEA-I, vimentin, |
| Tsai et al. [ | M | 56 | liver tumor | RA, OA knees, liver rupture | no | HBV | C | spleen | 9 W | Factor VIII, UEA-I, vimentin, CD34 |
| Tsai et al. [ | M | 30 | epigastralgia, general weakness | None | no | none | TAE+OP | none | 17 D | NA |
| Liang et al. [ | F | 59 | liver tumor | none | no | none | OP | none | 24 M | Factor VIII, vimentin |
| Tsai et al. [ | M | 60 | dyspnea, abdominal pain | DM, liver rupture | no | none | TAE | none | 24 D | NA |
| Hsiao [ | F | 82 | abdominal fullness, abdominal pain, nausea | HTN, CRI, PUD, L/C | no | none | none | none | 42 M | CD34 |
| Ho et al. [ | F | 68 | abdominal pain | uremia in HD, HTN, ureteral papilloma, liver rupture | no | none | OP+TAE+R/T | spine | 42 M | Factor VIII |
| Hsu [ | M | 72 | lower back pain | aortic aneurysm | no | none | OP | none | NA | NA |
| Cheng et al. [ | F | 58 | liver tumor | none | no | none | OP+C/T | none | 14 M | Factor VIII, vimentin |
DM = diabetes mellitus; HTN = hypertension; OA = osteoarthritis; CRI = chronic renal insufficiency; PUD = peptic ulcer disease; L/C = liver cirrhosis; OP = operation; TAE = transarterial embolization; C/T = chemotherapy; R/T = readiotherapy; C = conservative treatment; M = month; W = week; D = day; NA = not available.